接受每周利福喷丁联合异烟肼(3HP)方案治疗潜伏性结核感染者中的症状与全身性药物反应
本研究分析iAdhere研究(Study 33)中1002例接受3HP方案的潜伏性结核感染者的症状数据,发现77%报告至少1种症状,其中97%为1级或2级,多数在第一个月出现并缓解;11%符合全身性药物反应(SDR)标准,但其中48%完成了治疗。与SDR及停药相关的因素包括女性、年龄≥45岁和合并用药。
要点
- 1002例接受3HP者中77%报告至少1种症状,97%的症状为1级或2级。
- 111例(11%)符合SDR标准,其中53例(48%)完成了治疗。
- 女性、年龄≥45岁和合并用药与SDR及停药相关。
核心结论
- 多数接受3HP的患者报告症状,但多为轻度、出现早且无需停药即可缓解;发生SDR者中近半数能完成治疗。
- 患者和医务人员教育应侧重于区分应停用3HP的严重反应与可自行缓解的轻微症状。
研究设计与样本
- 对结核病试验联盟iAdhere研究(Study 33)中接受3HP的参与者症状数据进行分析。
- 检查基线和4次每月访视的症状报告模式,采用双变量分析和多变量回归模型识别与SDR相关的因素,计算风险比(RR)和95%置信区间(CI)。
主要发现
- 1002例接受3HP的参与者中,768例(77%)报告至少1种症状;这些症状中97%为1级(79%)或2级(18%)。
- 多数症状在第一个月出现并缓解。
- 111例(11%)参与者症状符合SDR标准,但其中53例(48%)完成了治疗。
- 与SDR及停药相关的因素包括女性(RR:2.05;95% CI:1.19-3.54)、年龄≥45岁(RR:1.99;95% CI:1.19-3.31)和合并用药(RR:2.26;95% CI:1.15-4.42)。
临床怎么用
- 患者和医务人员教育应侧重于区分应停用3HP的严重反应与可自行缓解的轻微症状(作者建议)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Three months of weekly rifapentine plus isoniazid (3HP) therapy for latent tuberculosis infection (LTBI) is recommended worldwide. The development of symptoms and systemic drug reactions (SDRs) on 3HP have not been fully characterized. We aimed to determine the patterns of symptom development and identify SDRs and associated factors in patients taking 3HP. METHODS: We analyzed symptoms data in participants receiving 3HP in the Tuberculosis Trials Consortium's iAdhere study (Study 33). We examined the patterns of symptom reporting across participants from baseline and 4 monthly visits. Bivariate analyses and multivariable regression models were used to identify factors associated with SDRs. Risk ratios (RRs) and 95% confidence intervals (CIs) were calculated. RESULTS: Among 1002 participants receiving 3HP, 768 (77%) reported at least 1 symptom; 97% of these symptoms were grade 1 (79%) or grade 2 (18%). Most symptoms developed in the first month and resolved. A total of 111 (11%) participants had symptoms that met criteria for SDRs; however, 53 (48%) of these participants completed therapy. Factors associated with SDRs and discontinuation included female sex (RR: 2.05; 95% CI: 1.19-3.54), age ≥45 years (RR: 1.99; 95% CI: 1.19-3.31), and use of concomitant medications (RR: 2.26; 95% CI: 1.15-4.42). CONCLUSIONS: Although most patients receiving 3HP reported symptoms, most were mild, occurred early, and resolved without stopping treatment. Among patients experiencing SDRs, nearly half were able to complete therapy. Patient and provider education should focus on differentiating severe reactions where 3HP should be stopped from minor symptoms that will resolve. Clinical Trials Registration. NCT01582711.
引用
- Sadowski C, Belknap R, Holland DP, et al. Symptoms and Systemic Drug Reactions in Persons Receiving Weekly Rifapentine Plus Isoniazid (3HP) Treatment for Latent Tuberculosis Infection. Clin Infect Dis. 2023. PMID: 36815322. doi:10.1093/cid/ciad083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。